BU-NOT-SET CONTACT US All20252024202320222021 May 04 2023 Recipharm makes senior appointment to head up biologics business unit, ReciBioPharm May 02 2023 FDA approves the manufacture of new microbiome-based therapeutic VOWST™ at Recipharm site April 28 2023 Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics April 04 2023 Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer March 09 2023 Recipharm's Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand December 05 2022 Recipharm announces extension of commercial manufacturing to support RedHill Biopharma's Talicia® to 2026 October 25 2022 Recipharm bolsters blow-fill-seal capabilities with Lab+ October 19 2022 Recipharm strengthens pre-filled syringe and cartridge offering with new investment September 29 2022 Transpire Bio announces second agreement with Recipharm for the development of two additional inhaled medicines April 11 2022 Recipharm completes US biologics acquisitions Pagination First page Previous page … Page 4 Current page 5 Page 6 Page 7 Next page Last page